To be upfront, the idea of Hims & Hers Health entered my inbox earlier this morning as a spam-like ticker recommendation. Initially, my instinct was to ignore it like every other piece of junk mail ...

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications. During ...

Hims & Hers launched an artificial intelligence agent embedded in its platform to help interpret biomarker lab results and ...

Digital healthcare continues to evolve across both direct-to-consumer and enterprise-focused platforms, with Hims & Hers ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth ...

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Hims & Hers Health Inc (NYSE:HIMS) shares are falling Thursday morning after the company announced a proposed convertible senior notes offering. What Happened: Hims & Hers Health announced plans on ...

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product ...

A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading care ...

Hims & Hers Health, Inc. HIMS is fundamentally built around expanding access to healthcare by shifting traditionally fragmented, in-person experiences into a more seamless digital model. Its platform ...

The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer. More than one in three people will develop cancer in their lifetime2 ...